Abivax S.A.
ABVX
Updated: 24/09/2026, 05:42:29
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
No summaries found.
- Share price
- $94.13
- Market cap
- $6.91B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Marc de Garidel
- Employees
- 80
- IPO date
- 20/10/2023
- Beta
- -0.248
- Last dividend
- $0.00
- Day range
- $92.57 – $98.37
- 52-week range
- $69.81 – $148.83
- 1-day performance
- -4.23%
- 1-year performance
- 34.84%
- Current drawdown (1Y)
- -36.75%
- CIK
- 0001956827
- CUSIP
- 00370M103
- ISIN
- US00370M1036
- Created
- 07/12/2025, 01:53:53
- Last update
- 24/09/2026, 05:42:29
Track Abivax S.A. with an AI analyst
See which prediction-market events move ABVX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
PRNewsWire • STOCK • 08/06/2026, 11:04:00
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX)
Newsfile Corp • STOCK • 04/06/2026, 17:24:00
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
Business Wire • STOCK • 03/06/2026, 22:53:00
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
GuruFocus • STOCK • 03/06/2026, 00:00:00
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
PRNewsWire • STOCK • 02/06/2026, 23:20:00
Biotech and Tech Stocks Plummet: Abivax S.A. (NASDAQ: ABVX) Leads Market Declines
Market Data • Market Data • 02/06/2026, 23:00:03
Abivax (NASDAQ:ABVX) Stock Plunges Amid Cancer Concerns, Jefferies Sets Bearish Price Target
Market Data • Market Data • 02/06/2026, 09:03:57
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial
WSJ • STOCK • 02/06/2026, 06:45:00
Abivax stock crashes as safety fears overshadow bowel disease drug trial win
Invezz • STOCK • 02/06/2026, 06:21:37
Abivax shares sink after key trial results for inflammatory bowel drug
Reuters • STOCK • 02/06/2026, 06:21:03
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
CNBC • STOCK • 02/06/2026, 05:20:30
Abivax's inflammatory bowel drug meets main goal of late stage trial
Reuters • STOCK • 01/06/2026, 20:38:56